Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Braz. j. med. biol. res ; 51(3): e6265, 2018. tab, graf
Article in English | LILACS | ID: biblio-889036

ABSTRACT

The receptor activator of nuclear factor κB ligand (RANKL)/RANK pathway plays an important role in the prognosis of several solid tumor types, but its role in gastric cancer prognosis has been poorly characterized. A total of 116 gastric cancer patients who underwent surgical resection were enrolled in this study. Expressions of RANKL and RANK in gastric cancer tissues were detected using immunohistochemical staining. Thirty-eight patients (33%) showed a high level of RANKL expression and 61 patients (53%) showed a high level of RANK expression. There was a positive correlation between expressions of RANKL and RANK (P=0.014, r=0.221). A high level of RANKL expression indicated shorter overall survival (OS) (P=0.008), and was associated with a higher pathological tumor/lymph node/metastasis (pTNM) stage (P=0.035), while no significant correlation was detected between RANK expression and clinicopathological parameters. RANKL also predicted poor prognosis in patients with high RANK expression (P=0.008) and Bormann's type III/IV (P=0.002). Furthermore, RANKL expression correlated with pTNM stage according to high RANK expression (P=0.009), while no significance was found in patients with low RANK expression (P=1.000). Together, our results revealed that high expression of RANKL could predict worse outcomes in gastric cancer especially combined with RANK detection, and thereby this pathway could be a useful prognostic indicator of gastric cancer.


Subject(s)
Humans , Male , Female , Middle Aged , Stomach Neoplasms/metabolism , Adenocarcinoma/metabolism , RANK Ligand/metabolism , Neoplasm Proteins/metabolism , Prognosis , Stomach Neoplasms/surgery , Stomach Neoplasms/mortality , Stomach Neoplasms/pathology , Immunohistochemistry , Adenocarcinoma/surgery , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Gene Expression Regulation, Neoplastic , China/epidemiology , Retrospective Studies , Statistics, Nonparametric , Neoplasm Grading , Neoplasm Staging
2.
Braz. j. med. biol. res ; 51(1): e6472, 2018. graf
Article in English | LILACS | ID: biblio-889011

ABSTRACT

Cetuximab is widely used in patients with metastatic colon cancer expressing wildtype KRAS. However, acquired drug resistance limits its clinical efficacy. Exosomes are nanosized vesicles secreted by various cell types. Tumor cell-derived exosomes participate in many biological processes, including tumor invasion, metastasis, and drug resistance. In this study, exosomes derived from cetuximab-resistant RKO colon cancer cells induced cetuximab resistance in cetuximab-sensitive Caco-2 cells. Meanwhile, exosomes from RKO and Caco-2 cells showed different levels of phosphatase and tensin homolog (PTEN) and phosphor-Akt. Furthermore, reduced PTEN and increased phosphorylated Akt levels were found in Caco-2 cells after exposure to RKO cell-derived exosomes. Moreover, an Akt inhibitor prevented RKO cell-derived exosome-induced drug resistance in Caco-2 cells. These findings provide novel evidence that exosomes derived from cetuximab-resistant cells could induce cetuximab resistance in cetuximab-sensitive cells, by downregulating PTEN and increasing phosphorylated Akt levels.


Subject(s)
Humans , Colonic Neoplasms/drug therapy , PTEN Phosphohydrolase/drug effects , Proto-Oncogene Proteins c-akt/drug effects , Exosomes/drug effects , Cetuximab/pharmacology , Antineoplastic Agents, Immunological/pharmacology , Tetrazolium Salts , Time Factors , Blotting, Western , Analysis of Variance , Caco-2 Cells , Cell Line, Tumor
SELECTION OF CITATIONS
SEARCH DETAIL